Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Summit Therapeutics Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 36.2× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Summit Therapeutics Inc for 16 Days on average.
| JPIN | SMMT | |
|---|---|---|
Market Cap | $378.77M | $13.71B |
Volume | 13,861 | 6,173,057 |
52-Week High | $77.80 | $26.38 |
52-Week Low | $64.96 | $12.43 |
Typical Hold Time | 120 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.03 with minimal daily movement (+0.12%). Technical indicators signal strong bearish momentum across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The ETF maintains a strategic focus on international value stocks but lacks current fundamental ratio data. Recent dividend activity shows a $0.51 distribution scheduled for September 2026.
The bearish technical setup dominates the near-term outlook, with resistance clustered at $74. Investment appeal hinges on international equity market recovery and the ETF's value strategy execution. Key risks include global market volatility and currency fluctuations affecting international holdings.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
